Seattle, Sept. 21, 2022 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the U.S. Medical Foods market is estimated to be valued at US$ 19,067.9 million in 2022 and is expected to exhibit a CAGR of 17.1% during the forecast period (2022-2030).
Key Trends and Analysis of the U.S. Medical Foods Market:
The rising prevalence of diabetes and malnutrition is propelling growth of market for medical foods in the U. S. For instance, according to Centers for Disease Control and Prevention (CDC), on January 18, 2022, there were about 37.3 million people who had diabetes in the U. S. which was 11.3% of the U.S. population.
Request Sample copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/3215
Key Market Takeaways:
U.S. Medical Foods market is expected to exhibit a CAGR of 17.1% during the forecast period due to increase in product launches by the key market players. For instance, on January 27, 2022, Danone S.A., a Spanish-French based multinational food-products corporation, announced launch of a new powder version of a pre-existing Souvenaid, a medical nutritional drink for supporting memory function in early stages of Alzheimer’s disease and mild cognitive impairment (MCI).
Among disease indication, irritable bowel syndrome (IBS) segment held a higher market share in 2021 owing to increasing patient pool suffering from IBS in the U.S. For instance, according to the International Foundation for Gastrointestinal Disorders (IFFGD) as on July 12, 2022, irritable bowel syndrome (IBS) is a chronic Gastrointestinal (GI) disorder affecting approximately 5 million people in the U.S. and about 38 women and 10 men per 100,000 people.
Competitive Landscape:
Key players operating in the U.S. Medical Foods market include Enterome SA, Yakult Honsha Co., Ltd., Abbott, ExeGi Pharma, LLC, VSL Pharmaceuticals, Inc., Entera Health, Inc., Meiji Holdings Co., Ltd., Danone, and Nestlé S.A.
Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/3215
Market Segmentation:
- U.S. Medical Foods Market, By Food Type:
- Prebiotics
- Probiotics
- Probiotic Foods
- Probiotic Supplements
- Food Supplements
- U.S. Medical Foods Market, By Disease Indication:
- Inflammatory Bowel Disease
- Ulcerative Colitis
- Cohn’s Disease
- Irritable Bowel Syndrome
- Others
- Inflammatory Bowel Disease
- U.S. Medical Foods Market, By Distribution Channel:
- Hospitals
- Retail Channel
- Online Channel
Related Market Intelligence Reports:
Rx Medical Food Market, by Product Type (Pills, Powder, Liquid and Others (wafers, chewables, and bars)), by Therapeutic Application (Pain Management, Pain Management, Neurological Disorder, GI Disorder, Pulmonary Disorders, Metabolic Disorders, and Others (fibrosis, dialysis, AIDS, etc.)) by Distribution Channel (Retail Pharmacies and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 – 2027
Human Microbiome Market, by Product Type (Foods (Probiotics, Prebiotics, and Medical Foods), Fecal Microbiota Transplant (FMT), Microbiome Drugs, and Others), by Disease Indication (Clostridium Difficile Infection (CDI), Inflammatory Bowel Disease (IBD), Metabolic Disorders, Autoimmune Disorders, Allergic Diseases, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2021 – 2028
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
